

Agenda EU-JAMRAI 2 Annual Meeting 12-13 March 2025

Bizkaia Aretoa – UPV/EHU Abandoibarra Etorb., 3, Abando, 48009 Bilbo, Bizkaia



Location

Meeting room: Mitxelena Auditorium

Organisers

Biosistemak (KG), WPI

Day I – I2 th March, 2025		
08:30 – 09:00	Welcoming participants	
09:00 – 09:10	Introduction Day I Marie-Cécile Ploy, EU-JAMRAI 2 coordinator	
09:10 – 09:40	 Representative from the Basque country TBC (10') European Commission, DG Sante, Velina Pendolovska or Julia Langer (10') WOAH, Javier Yugueros-Marcos on behalf of the Quadripartite (10') 	
09:40 – 11:15	Session 1: Toward an integrated One Health surveillance of AMR in Europe 1- Introduction (5') 2- Animal & environmental surveillance (40') Progress update from EU-JAMRAI 2 on animal surveillance (EARS-Vet) (10') Progress update from EU-JAMRAI 2 on environmental surveillance (EARS-Env) (10') Panel discussion: The future and sustainability of the EARS Vet and EARS Env networks (20') • European Commission Unit A1, Ariane Vander Stappen or Béatrice Marquez Garrido • European Commission Unit B2, Velina Pendolovska or Julia Langer • ECDC, Dominique Monnet • EFSA, Ernesto Liebana • EEA, Caroline Whalley • WHO-Europe, Peter Hoejskov 3- Human surveillance & efforts to move forward a One Health integrated surveillance (40') Progress update from EU-JAMRAI 2 on human surveillance (10') Progress update from EU-JAMRAI 2- efforts to move forward a One Health integrated surveillance (10') Panel discussion: How to move forward a One Health integrated surveillance? (20') • European Commission Unit A1, Ariane Vander Stappen or Béatrice Marquez Garrido • European Commission Unit B2, Velina Pendolovska or Julia Langer • ECDC, Dominique Monnet • EFSA, Ernesto Liebana • EEA, Caroline Whalley • WHO-Europe, Peter Hoejskov 4- Wrap up (10')	

11:15 – 11:45	Coffee break
11:45 – 12:40	Session 2 – Ist half: Improving implementation in AMS and IPC in a One health perspective I - Why linking AMS and IPC - common goals, shared objectives and targets 2 - Panel discussion: The importance of AMS & IPC strategies (25') Panellists: • European Commission Unit F5, Iwona Decewicz • ECDC, Diamantis Plachouras • EEA, Caroline Whalley • WHO, Ana Paula Coutinho • WOAH, Ana Mateus • FAO, (TBC) • EUCIC, Gabriel Birgand • ESGAP, Lucy Catteau • Drive-AMS, Jeroen Schouten 3 - Behaviour change as a transversal approach to address both AMS and IPC (25')
12:40 – 12:50	Photoshoot
12:50 – 14:00	Lunch Break
14:00 – 15:40	Session 2 – 2 nd half: Improving implementation in AMS and IPC in a One health perspective 4- Work from EU-JAMRAI 2 on AMS & IPC (presentations + Q&A) Efforts in human Health (25') Efforts in animal health (25') 5- Wrap-up & meeting the targets (5') 6- Panel discussion: The interlinked impact of our One Health activities (AMS and IPC) — a joint perspective (20') Panellists: • European Commission Unit F5, Iwona Decewicz • ECDC, Diamantis Plachouras • EEA, Caroline Whalley • WHO, Ana Paula Coutinho • WOAH, Ana Mateus • FAO, (TBC) • EUCIC, Gabriel Birgand • ESGAP, Lucy Catteau • Drive-AMS, Jeroen Schouten

15:40 – 16:00	Coffee break
16:00 – 17:20	Coffee break Session 3: Improving access to ensure optimal treatment options for humans and animals in Europe 1- Introduction - Why is EU-JAMRAI-2 focusing on access and what have been done Sofia Linnros, EU-JAMRAI 2, Sweden (5') 2- Focus on veterinary products: the case of access to benzylpenicillin for veterinary use (35') Why is the supply of benzylpenicillin for veterinary use in jeopardy? Cristina Muñoz Madero, AEMPS, Spain (10') Panel discussion + Q&A (25'): Moderator: Christine Årdal, EU-JAMRAI-2, Norway Panellists: Tita-Maria Muhonen, Finland Cristina Muñoz Madero, Spain Pascal Beyens, Access Vet Med Ana Maria Azaceta Avila, EMA 3- Focus on human products: Improving the availability of "access" antibiotics for human use (30') Which "access" antibiotics for human use are EU-JAMRAI-2 focusing on? Sofia Linnros, EU-JAMRAI 2, Sweden (5') Panel discussion + Q&A (25'): Moderator: Christine Årdal, EU-JAMRAI-2, Norway Panellists: Emma Keuleyan, Bulgaria Michael Borg, Malta Alban Dhanani, France Emilija Matelytė, EMA
	 Boumediene Soufi, Medicines for Europe 4- Wrap up: Looking ahead to next year (10')
17:20 – 17:30	Conclusion Day I (TBC)
17:45 – 19:00	Visit of the Guggenheim Museum
19:00 – 20:30	Free time
20:30	Social event – Cocktail Guggenheim Museum Restaurant

Day 2 – 13 st March, 2024		
8:30 - 09:00	Welcoming participants	
09:00 – 09:10	Introduction Day 2 Marie-Cécile Ploy, EU-JAMRAI 2 coordinator	
09:10 – 09:30	 Keynotes Day 2 European Patient Forum, Yann Heyer (10') Farmer stories (TBC- 10') 	
09:30 - 10:50	Session 4: Raising global awareness on AMR in Europe. 1- Ice breaker (8') 2- Efforts to make EU-JAMRAI 2 visible? (7') Video + presentation 3- Renewing AMR Communication (30') Video + presentation Panel discussion - Renewing AMR Communication • WOAH, Javier Yugueros-Marcos • UNEP, Pablo Sagredo • ECDC, Sarah Earnshaw Blomquist • The AMR Narrative, Vanessa Carter 4- Raising awareness on AMR with a GLOCAL approach (30') Video + presentation Panel discussion - Raising awareness on AMR with a GLOCAL approach • European Commission, Unit A3, Edward Demicoli • EFSA, Giovanni Mancarella • EU-JAMRAI 2 COM Network Members from Croatia, Selma Bošnjak • EU-JAMRAI 2 COM Network Members from Iceland, Rebekka Aldís Kristinsdóttir Valberg 5- Wrap up — Goals for next year (5')	
10:50 - 11:20	Coffee Break	
11:20 - 12:40	Session 5: Building a bridge from actions to One Health policies with a sustainable impact 1. Introduction (5') 2. Why do we want to build this bridge? (20') EU-JAMRAI 2 presentation (5')	

	 European Commission Unit AI, Ariane Vander Stappen or Béatrice Marquez Garrido (7') OECD, Michele Cecchini (7') 3. What do we want to achieve? (25') EU-JAMRAI 2 presentation (5') Panel discussion (20'): 3 liaisons officers from EU-JAMRAI (TBC) 4. How EU-JAMRAI2 can support? (30') EU-JAMRAI 2 presentation (10') Panel discussion (15'): ECDC, Dominique Monnet EFSA, Ernesto Liebana
12:40 - 12:50	Conclusion Day 2 (TBC)
12:50 - 14:00	Cocktail for participants

EU-JAMRAI2 receives funding from the European Union's EU4Health programme under grant agreement No 101127787. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.

